Rheumnow
Do we need more IL-17 and JAK Inhibitors in Spondyloarthritis?
- Author: Vários
- Narrator: Vários
- Publisher: Podcast
- Duration: 0:05:04
- More information
Informações:
Synopsis
Dr. Eric Ruderman shares his perspectives on the following abstracts being presented at Eular 2024 in Vienna, Austria: OP0195 Sonelokimab IL 17 A/F nanobody inhibitor LB0005 Izokibep IL17A nanobody inhibitor POS0803 Vunakizumab, another IL17A inhibitor OP0138 TAK-279 phase 2B selective TYK2 inhibitor Zasocitinib
